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Alpha-hemoglobin-stabilizing protein (AHSP) is an erythroid-speciﬁc protein that acts as a molecular chaperone for the free α
chains of hemoglobin. Evidence strongly suggests that AHSP participates in hemoglobin synthesis and may act to neutralize the
cytotoxic eﬀects of excess free alpha-globin subunits that accumulate both in normal and beta-thalassemic erythroid precursor
cells. As such, AHSP seems to be essential for normal erythropoiesis, and impaired upregulation of AHSP may lead to premature
erythroid cell death, resulting in ineﬀective erythropoiesis. Reduced AHSP mRNA expression has been associated with clinical
variability in some cases of β-thalassemia. It has been shown that αHb variants may also impair AHSP-αHb interactions, leading
to pathological conditions that resemble α-thalassemia syndromes. The aim of this paper is to summarize current information
concerning the structure and function of AHSP, focusing on its role in normal erythropoiesis and its relevance in health and
disease.
1.Introduction
The term “molecular chaperone” was ﬁrst used in 1978 to
describe the in vitro properties of nucleoplasmin, which
prevents the aggregation of folded histone proteins with
DNA during the assembly of the nucleosome [1]. However,
the concept of the molecular chaperone as a protein that
can interact with other proteins and help them to reach
their ﬁnal, active conformation was established only in
1987 [2]. Molecular chaperones are currently deﬁned as
“proteins whose role is to mediate the folding of certain
other polypeptides and, in some instances, their assembly
into oligomeric structures, but which are not components
of these ﬁnal structures” [3]. As such, molecular chaperones
participate in a variety of physiological processes related
to the correction of the structure of proteins during their
synthesis and after their release from ribosomes, and more
than 25 diﬀerent protein families described as chaperones
have been reported [4].
Alpha-hemoglobin-stabilizing protein (AHSP) is a small
protein that binds speciﬁcally to the free alpha globin chain
(αHb) of hemoglobin (Hb). The main function of AHSP
appears to be to regulate the stability, folding, and assembly
of the αHb subunit. The biochemical properties of the
AHSP-αHb complex led to the classiﬁcation of AHSP as a
novel type of chaperone. Like the small heat shock proteins
(sHSPs), a family of molecular chaperones, AHSP presents
low molecular weight and ATP-independent chaperone-like
activity. However, unlike other molecular chaperones, it
does not form oligomeric complexes and is highly tissue
and substrate speciﬁc [5, 6]. AHSP plays an important
role in the physiological process of erythropoiesis [5, 7]
and may also be a modulator of pathological conditions
[8–11]. Since chaperone proteins are essential for native
protein conformation and defective chaperone proteins may
be associated with diseases, the aim of this paper is to
summarize the current research concerning the structure
and function of AHSP, focusing on its role in normal2 Biochemistry Research International
erythropoiesis and its possible importance as a modiﬁer of
β-thalassemia.
2.Hemoglobin: Functionand Biosynthesis
Hemoglobin is an essential protein for life, since it is
responsible for binding oxygen in the lungs and delivering
it to all tissues and organs in the body in a well-controlled
manner. The major functional adult human Hb (HbA) is a
heterotetramercomposedoftwo alpha-(αHb)andtwobeta-
(βHb) globin chains, each containing a prosthetic group-
Heme [12].
Biosynthesis of hemoglobin occurs exclusively in cells
of erythroid lineage and, therefore, is intimately related
to erythropoiesis. Hemoglobin synthesis begins at the
proerythroblast phase, continues at a high rate throughout
the basophilic and the polychromatophilic erythroblast
stages, and persists at a very low rate in the reticulo-
cytes. This multistep process is complex and controlled
by two distinct gene clusters: the α-like globin cluster
located on chromosome 16 and the β-like globin cluster on
chromosome 11; and is highly regulated to ensure that αHb
and βHb are produced at a stoichiometric rate. During the
ﬁrst step of HbA assembly, αHb and βHb chains combine
to form the α1β1 interface, which involves hydrophobic
and electrostatic interactions. In a second step, two dimers
associate to form the α1β2 interface, which involves more
polar interactions [12]. Isolated αHb is diﬀerent from βHb
monomers in structural stability, where βHb subunits are
more stable than αHb. After covalent association with heme,
βHbchains self-associate toformhomotetramers (β4),called
HbH. However, these tetramers are not functional due to
their high aﬃnity for oxygen. During auto-oxidation, αHb
monomers tend to produce reactive oxygen species (ROS)
via chemical reactions catalyzed by heme-iron [13]. Free
αHb monomers are highly unstable and do not self-associate
to form tetramers but tend to aggregate and precipitate,
resulting in damage to the membrane and triggering the
apoptosisoferythroidprecursors (ineﬀectiveerythropoiesis)
and a shortened lifespan of circulating red blood cells [14,
15].
Before the discovery of AHSP protein, it was postulated
that the nascent polypeptide chains readily associate to form
dimers (αβ), and soon after, to form tetramers (α2β2)b y
a spontaneous process requiring no other molecules [16,
17]. This concept changed after Kihm and colleagues [6]
showed that the small protein AHSP, encoded by a gene
ﬁrst described as EDRF [18], could form a complex with
free αHb, preventing its precipitation and neutralizing its
deleterious eﬀects. Currently, AHSP is known to play an
importantroleinhemoglobinassemblyandcouldhavemed-
ical implications, since imbalances in globin synthesis are
associated with serious human diseases [14]. In thalassemia
disorders, mutations in the α-globin (HBA)o rβ-globin
(HBB) genes lead to an excess of free βHb or αHb subunits,
respectively. Due to the great variability in β-thalassemia
phenotype and the role of AHSP in preventing the cytotoxic
eﬀects of free αHb in excess, it has been suggested that AHSP
is a potential modiﬁer of this disease.
3.AHSP:An ErythroidMolecular Chaperone
AHSP is a protein expressed in hematopoietic tissues (bone
marrow in humans and fetal liver, spleen, and bone marrow
in mice) and exclusively by cells of the erythroid lineage
[6, 18]. AHSP forms a stable but reversible complex with
free αHb to stabilize its structure and limit its chemical
reactivity. This interaction prevents αHb aggregation and
precipitation in solution and in live cells and therefore
maintains αHb available for incorporation into HbA [6, 19].
The AHSP-αHb interaction also inhibits ROS production
and, therefore, oxidative damage [20, 21]. AHSP does
not bind to the βHb subunit or tetrameric HbA. Indeed,
structural analysis of AHSP-αHb complex revealed that
AHSP and βHb compete to bind to αHb in the same region,
called the α1β1 interface [5]. βHb aﬃnity to αHb is stronger
andwinsthiscompetition,displacingAHSPtoformtheHbA
molecule. Consistent with the role of a molecularchaperone,
in addition to itsability to stabilize αHb, AHSPis also able to
promote refolding of denatured αHb [22].
4. AHSP:Gene Structureand Expression
The AHSP gene is located on human chromosome 16
(GenBank accession number AC106 730.2). The genomic
structure of AHSP is organized in three exons and two
introns, comprising approximately 1.8kb. The AHSP mRNA
encodes a protein of 102 amino acids with a molecular mass
of 12kDa; the protein is highly conserved in humans, pigs,
cows, and rats [6].
Identiﬁcation and characterization of the regulatory
elements that control AHSP gene expression have important
implications for normal erythropoiesis and the pathogen-
esis of hemolytic disorders. Like many other genes that
participate in hemoglobin synthesis, AHSP gene expression
is controlled by GATA-1 [6], a transcription factor that
is essential for the survival and maturation of lineage-
committed erythroid precursors. There is evidence that Oct-
1[ 23]a n dE K L F[ 24–26], two transcription factors that have
a critical role in erythropoiesis, also participate in the control
of AHSP gene expression.
The AHSP gene promoter comprises the region from
−170 to +269 and includes the 5 -ﬂanking DNA and intron
1. There are 5 consensus GATA-1 binding sites in this
minimal promoter region (−179/+290), three in the 5 -
ﬂanking region and two in intron 1. An Oct-1 consensus site
also exists in the AT-rich region ofAHSP intron 1 [23].EKLF
directly regulates the AHSP gene by binding to a site at −60
inthehumanAHSPpromoterregionthatissituatedbetween
two conserved GATA-1 binding sites at −47 and −90. Keys
and colleagues [25]p r o p o s e dt h a tG A T A - 1a n dE K L Fa r e
coregulators ofAHSP gene expression during erythropoiesis.
Molecular analysis of the AHSP gene has identiﬁed
several single nucleotide polymorphisms (SNPs) and gene
haplotypes [9, 10, 27]. An SNP within the intron 1 of AHSPBiochemistry Research International 3
(12391 G > A SNP) alters the binding site for Oct-1, and
there is evidence that this SNP can reduce AHSP expression
in vivo [10]. Human AHSP gene expression can be aﬀected
by the iron status via an iron sensor system, composed of
iron responsive elements (IREs) and iron regulatory proteins
(IRP). A stem-loop structure that resembles the IRE was
identiﬁed in the 3 UTR of AHSP mRNA. It has been shown
that these IRE-like structures can interact with IRPs and that
the IRE-IRP interactions can be disrupted by iron, resulting
in destabilization of AHSP mRNA. These data suggest that
AHSP gene expression is downregulated in the excess of iron
and upregulated during iron deﬁciency [28].
5.AHSP:ProteinStructureand
Mechanism of Action
The structure of AHSP was determined by nuclear magnetic
resonance spectroscopy (NMR) and X-ray crystallography
[20, 21, 29]. In its native state, AHSP is comprised of a
bundle of three elongated antiparallel α-helices and is con-
formationally heterogeneous. AHSP exists in two forms, cis
andtrans,thataredistinguished becauseofthearrangements
of the loop region between helices 1 and 2 due to cis/trans
isomerization of residue Pro30. However, once AHSP binds
to αHb, Pro30 adopts just one conformation [29].
AHSP forms a simple heterodimer with αHb via the
α1 portion of the α1β1 interface in HbA [5], which is
the same interface as that of the βHb interaction. The
intermolecular contacts between αHb and AHSP are less
extensive than those between αHb and βHb and this may
explain why AHSP is replaced by βHb [11]. AHSP binds
apo-αHb (without heme) and holo-αHb (with heme iron),
either in the oxidized (FeIII) or reduced (FeII) states [5, 6,
20, 21]. Data suggest that the interaction of wild-type AHSP
(AHSPWT)w i t hn a s c e n tαHb promotes correct folding into
a native state, which is independent upon heme, conferring
protection from proteolytic digestion. Consistent with the
roleofamolecularchaperone,AHSPalsopromotesrefolding
of denatured apo-αHb [22].
Reports indicate that binding of AHSP to oxy-αHb
(FeII) is associated with structural alterations in the heme
pocket. These initial changes are reversible and result in
a structure that exposes the oxygen-binding site [21, 30].
If the oxy-αHb-AHSP interaction persists, the structure of
the heme pocket is altered further, auto-oxidation occurs
and the heme-bond iron is converted to a ferric form in
a Fe(III) bis-histidyl complex. This hemichrome structure
inhibits the reaction of Fe(III)-αHb with oxidants such as
hydrogen peroxide, conferring resistance to hemin loss and
denaturation. AHSP, bound to both the oxidized (ferric) and
reduced (ferrous) αHb forms, can be replaced by oxy-βHb
to generate functional HbA [30]. These data suggest that,
in the absence of βHb, AHSP maintains the excess αHb in
a reversible inert state to limit the production of damaging
ROS.
The kinetics of αHb binding-dissociation to AHSP was
investigated by Mollan et al. [31]. The authors used the
ﬂuorescence energy transfer technique to study the rate of
association and dissociation of the AHSP-αHb complex.
The αHb and βHb chains do not ﬂuoresce due to high
quenching of tryptophan or tyrosine ﬂuorescence by the
heme group, an eﬃcient energy acceptor. AHSPhas no heme
group and demonstrates an intrinsic ﬂuorescence typical of
an exposed tryptophan at position 44. As such, quenching
of ﬂuorescence of the AHSP by binding to αHb was used to
measure the rate of AHSP-αHb complex formation. Starting
the experiment with isolated αHb and AHSP proteins, these
authors found that the apparent association rate constant
for AHSP to αHb (k  ≈ 10μM
−1s−1) is greater than the
association rate constant for (deoxy)αHb to (deoxy)βHb
(k  ≈ 0.5μM
−1s−1)i nin vitro experiments. The βHb
chains were added to follow the displacement of αHb from
AHSP, and the increase in ﬂuorescence intensity was used
to detect the extent of AHSP dissociation. The dissociation
equilibrium constant (Kd)o f∼10−2 μMf o rt h eA H S P - αHb
complex was compared with the Kd of ∼10−6 μMf o rt h e
αHb-βHb dimer. Thus, these data show that AHSP binds
faster to αHb than βHb (∼20 times) and also that AHSP has
al o w e ra ﬃnity for αHb when compared with the aﬃnity of
βHb for αHb (∼10.000 times). These kinetic properties of
AHSP are in agreement with its chaperone function, that is,
fast binding to free αHb to prevent its degradation and rapid
release of αHb for Hb assembly [31].
6.AHSPinNormalErythropoiesis
The main characteristic of erythropoiesis is the massive
synthesis of hemoglobin. As stated earlier, αHb and βHb
subunits must be produced in equilibrium to prevent their
harmful eﬀects. However, there is experimental evidence
that αHb is produced in slight excess during normal
erythropoiesis. The identiﬁcation of the AHSP gene by Miele
etal.[18]andtherecognitionofitsabilitytospeciﬁcally bind
to free αHb by Kihm et al. [6] highlighted a new homeostatic
mechanism to handle the harmful excess of free αHb during
HbA production.
Using a murine model, Kihm et al. [6]r e p o r t e dt h e
ﬁrst evidence that AHSP plays an important role in in vivo
erythropoiesis. Transgenic mice, in which the entire protein-
coding region of Ahsp gene (Ashp−/−) was ablated, exhibited
hematological alterationsconsistent with ineﬀectiveerythro-
poiesis that were similar to those observed in β-thalassemia.
Unexpected results were obtained in a murine model of
compound mutants lacking both Ahsp genes (Ashp−/−)a n d
1o f4α-Hb genes (αHb
−α/αα); these mice exhibit a more
anemic phenotype than expected. These ﬁndings suggest
that AHSP plays an important role in erythropoiesis even
when the pool of free αHb is not present [22], probably
because AHSP stabilizes newly synthesized αHb to augment
its incorporation into HbA.
Theexpression oftheAHSP geneduring humanerythro-
p o i e s i sw a sﬁ r s tr e p o r t e db yD o sS a n t o se ta l .[ 7]. Diﬀerenti-
ation of erythroid progenitor cells from healthy volunteers
was achieved by a two-phase liquid culture system, stim-
ulated with erythropoietin. Cell surface marker expression
was accompanied during cellular diﬀerentiation using ﬂow
cytometry and by morphological analyses. Quantiﬁcation
of AHSP, HBA,a n dHBB gene expression was determined4 Biochemistry Research International
by the real time polymerase chain reaction at four distinct
stages of erythropoiesis: during the earlier phase in which
proerythroblasts begin to be discernible (3-4 days of phase
II); during the intermediate phase characterized by the
appearance of basophilic erythroblasts (5–7 days) and an
increasing proportion of polychromatic and orthochromatic
erythroblasts(8–10days),and during the latephase in which
orthochromatic erythroblasts predominate (11–14 days).
Consistent with erythropoiesis physiology, higher levels of
HBA expression were observed during the intermediate
phase, in which polychromatic and orthochromatic ery-
throblasts predominate, and it was followed by a decrease
in more mature precursors, present during the late phase.
Interestingly, AHSPexpressionduringnormalerythropoiesis
showed a pattern similar to that of HBA, with the highest
expression at the stage where hemoglobin biosynthesis
is more intense. These data demonstrated that the ratio
between AHSP and HBA expression is conserved in all stages
of normal erythropoiesis and strongly suggest that AHSP
plays an important role in human erythropoiesis [7].
To better understand the relationship between AHSP
expression, HbA formation, and the consequences of a
reduced AHSP synthesis in human red blood cells, an RNA-
interference knockdown of AHSP expression was established
both in hemin-induced K562- cells and human hematopoi-
etic stem cells (CD34+). Decreased AHSP expression levels
were observed in response to AHSP knockdown in both K-
562 and EPO-induced CD34+ cells. The decrease in AHSP
expression was associated with a remarkable αHb precipita-
tion in erythroid precursors, when compared with negative
control cells. Signiﬁcant increases in ROS production and
cell death were also observed [19]. These ﬁndings were in
agreement with the data obtained in models of transgenic
mice [6, 8] and provided further evidence that AHSP plays
an important role in human erythropoiesis. Data from in
vitro and in vivo studies suggest that AHSP participates
in HbA formation by both preventing αHb precipitation
and degradation or by enhancing proper folding and heme
insertion [22, 32–34].
7.AHSPasaβ-ThalassemiaModiﬁer
Although β-thalassemia results from reduced βHb synthesis,
the pathophysiology of this disease is determined by the
level of free αHb chains that cause oxidative damage of red
blood cells. The marked variability in clinical severity of β-
thalassemiahasbeenattributedtoenvironmentalandgenetic
factors, including hereditary persistence of fetal hemoglobin
(HPFH) and coexistence of α-thalassemia [35]. However,
these factors cannot explain the phenotypic variability in
many cases of β-thalassemia.
Considering the biological and biochemical properties
of AHSP, it is natural to speculate those AHSP muta-
tions, leading to its reduced expression or altered function,
could modify the clinical characteristics of β-thalassemia.
Galanello et al. [36]p r o v i d e dt h eﬁ r s te v i d e n c et h a tA H S P
couldmodulateβ-thalassemia. Theyreported theassociation
of reduced AHSP mRNA expression and a more severe
phenotype among individuals with identical β-thalassemia
genotypes in two unrelated Sardinian families. Observations
from a murine model of β-thalassemia intermedia provided
further evidence for this possibility. The phenotype of
transgenic mice with β-thalassemia intermedia is exacer-
bated by concomitant AHSP loss [8]. AHSP mutations
in β-thalassemia patients are uncommon and, to date,
the association between AHSP mutation and β-thalassemia
variability has not been well established; however, there exist
some reports showing the association between β-thalassemia
severity and AHSP genotype [10, 27, 37].
The investigation of AHSP sequence in healthy and β-
thalassemia individuals from ﬁve diﬀerent regions of the
world identiﬁed a single nucleotide change in the third exon
of the AHSP gene, resulting in a protein with an isoleucine
at position 75, instead of an asparagine (AHSPN75I). This
uncommon missense mutation does not aﬀect the aﬃnity
of AHSP for αHb and the oxidation of the ferric oxy (FeII)-
αHb to the ferrous (FeIII) form is induced at a similar rate,
whencomparedtotheAHSPWT.H o w ev er ,AHSP N75I showed
a reduced ability to inhibit ROS production by αHb. Thus,
there is evidence that the mutant protein is less eﬀective
against the oxidative eﬀects of free αHb. This mutation
demonstrated clinical consequences in a patient, found to
be compound heterozygous for AHSPN75I and β-thalassemia
(β0 Codon 39 C > T), who presented with a severe anemia
that required blood transfusion. However, when inherited
without any thalassemia mutation, the heterozygous state
does not show clinical relevance [10, 38].
Two other missense mutations, AHSPD29V (12750 A >
T) and AHSPV56G (12831 T > G) were identiﬁed in a
populational study to assess the eﬀect of AHSP on the
phenotype of β-thalassemia patients of Southern China, a
region with a high prevalence of this genetic condition.
However, neither of these mutations were associated with
signiﬁcant phenotypic variability among patients [39].
Lai et al. identiﬁed several sequence variants, including
a Tn-homopolymer in the AHSP promoter region. In a
family study, this AHSP variant, speciﬁcally the shorter
homopolymer length (T15), was associated with reduced
AHSP-mRNA and protein expression in an individual with
thalassemia syndrome (genotypeβ0 39–850 C-T/βN, αHb
ααα/αα,
and T15/T18), when compared with her mother (genotype
β0 39–850 C-T/βN, αHb
ααα/αα,a n dT 18/T18)[ 9]. However, no
signiﬁcant diﬀerences in hematological parameters were
found among β-thalassemia carriers from Southern China
who were T15 homozygous (14 cases), T18 homozygous (223
cases) or T15/T18 heterozygous (128 cases) [39]. Conversely,
Wang et al. showed that the introduction of a transgenic
human-AHSP gene is able to neutralize excess αHb in a
murine model of β-thalassemia (βIVS-2-654) and, as a con-
sequence, ameliorate the phenotype of these animals [40].
Despite the partial improvement observed in the approach
described, these data support the hypothesis that AHSP
could be an adjuvant in gene therapy to treat β-thalassemia.
8.AHSPandα-Thalassemia-LikeSyndromes
As stated previously, AHSP expression levels and protein
function are important for the normal physiology of redBiochemistry Research International 5
blood cell production and could have a relevant impact
on the phenotype of β-thalassemia. The level of AHSP
mRNA from healthy individuals was not found to correlate
with age or sex, but varied considerably, up to threefold in
reticulocytes [9] and 10-fold in cultured erythroblasts [41].
This variability is probably associated with AHSP polymor-
phisms in regulatory regions since naturally occurring AHSP
mutations that impair gene expression or protein function
are rare [9, 10, 27].
The mutant AHSPV56G described by Pissard et al. [42]i s
the ﬁrst mutation in the AHSP gene that can be associated
with α-thalassemia-like syndromes. The authors report the
case of a child that presents with microcytic, hypochromic
anemia, 3% of Hb Bart’s, a normal globin gene pattern
but a homozygous state for the AHSPV56G mutant. The
parents and the ﬁrst son were heterozygous carriers for
this mutation and were clinically normal [42]. The clinical
feature observed in the homozygous state may be explained
by the altered biochemical and biophysical properties of
the mutant protein and its association with an haplotype
characterized by a decrease in AHSP expression [42, 43].
This mutation changes the Valine residue at position 56 to a
Glycine.This residue islocated atthe cornerbetween thetwo
α-helices [39, 43]. Investigating the kinetic properties of the
AHSPV56G, Brillet and coworkers demonstrated that despite
its thermal instability (Tm of 42◦C), the binding to αHb and
formation of the AHSPV56G-αHb complex is not aﬀected.
The association rate constant is similar to that of AHSPWT
(k  ≈ 20μM
−1s−1). In contrast, the AHSPV56G-αHB complex
dissociates faster (dissociation rate of 0.5s−1)t h a nA H S P WT
(2s−1), thus it seems that this reduced contact time does not
allow the complex to complete the structural modiﬁcations
required to stabilize αHb chains [43].
On the other hand, αHb mutations may also result in
impaired AHSP-αHb interactions and could be responsible
forthalassemia-likephenotypeswithoutexplanationinsome
patients. Indeed, this defective interaction has been shown
for several αHb variants, such as Hb Constant Spring and
Pakse [44]; Hb Groene Hart [45, 46]; Hb Foggia [47],
and several other αHb variants [48, 49]. The structural
abnormalities of these αHb variants are located at the AHSP
binding interface, therefore impairing their interaction.
Failed interactions may lead to destabilization of native αHb
folding [48]. However, the mechanisms involved in this
defective process are not well known, and further studies are
required to betterunderstand the biochemical and biological
consequences of αHb variants.
9.Summaryand Perspectives
Molecular chaperones are essential for the maintenance of
their target proteins. AHSP is only expressed in erythroid
cells, speciﬁcally binds to αHb, and does not bind to βHb
or HbA. As a molecular chaperone for αHb, AHSP plays
at least three important roles: (a), promotes proper folding
of nascent αHb, independently of the presence of iron,
conferring resistance to proteolytic digestion; (b), inhibits
auto-oxidation of holo-αHb, converting the bound heme
iron to an inert hemichrome structure (c) it promotes
refolding of the denatured protein. As such, AHSP seems
to be essential for normal erythropoiesis. Impaired up-
regulation of AHSP leads to premature erythroid cell death,
resulting in ineﬀectiveerythropoiesis.ReducedAHSPmRNA
expression has been associated with clinical variability in
some cases of β-thalassemia. It has been shown that αHb
variants can also impair AHSP-αHb interactions, lead-
ing to pathological conditions that resemble α-thalassemia
syndromes. As such, AHSP mutations may be considered
when clinical severity is not explained by the β-thalassemia
genotype, or in undiagnosed α-thalassemia-like syndromes.
Whilst available evidence strongly suggests that AHSP
promotes the synthesis of HbA in red blood cells, future
studies will help to better understand the molecular inter-
actions of hemoglobin assembly and the relevance of these
mechanisms in health and disease.
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